List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 34 studies with search of:   "ataxia-telangiectasia"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Active, not recruiting Study for Treatment of Cancer in Children With Ataxia-Telangiectasia
Condition: Ataxia-Telangiectasia
Interventions: Drug: vinblastine, vincristine, prednisone, daunorubicin;   Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase;   Drug: etoposide, cytarabine, mercaptopurine;   Drug: dexamethasone, procarbazine;   Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy
2 Completed Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)
Condition: Ataxia Telangiectasia (AT)
Intervention: Drug: Conjugated pneumococcal vaccine (Prevenar)
3 Recruiting Baclofen Treatment of Ataxia Telangiectasia
Condition: Ataxia Telangiectasia (A-T)
Intervention: Drug: Baclofen or Placebo
4 Completed Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism
Conditions: Hypertension;   Coronary Arteriosclerosis
Interventions: Drug: telmisartan 40 mg;   Drug: placebo 40 mg
5 Completed Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T.
Condition: Neoplasm Metastases
Intervention:
6 Recruiting Role of AT1-Receptor Blockers in Insulin-Induced Vasodilation.
Conditions: Hypertension;   Insulin Resistance;   Microcirculation
Interventions: Drug: Irbesartan;   Drug: Felodipine;   Drug: Placebo
7 Recruiting Implantable Cardioverter Defibrillators And Magnetic Resonance Imaging of the Heart at 1.5 Tesla
Conditions: Defibrillators, Implantable;   Heart Failure, Congestive
Intervention:
8 Completed GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence
Condition: Atrial Fibrillation
Interventions: Drug: Valsartan;   Drug: Placebo
9 Active, not recruiting Long-Term Antibody Persistence at 1, 3 and 5 Years After a Booster Dose of GSKBiologicals Hib-MenCY-TT Vaccine Compared to ActHIB
Conditions: Haemophilus Influenzae Type b Infections;   Meningococcal Infections
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b & Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014;   Biological: Hib conjugate vaccine
10 Recruiting Comparison of 4.0 mg/kg Sugammadex at 1-2 PTC in Renal or Control Patients (19.4.328)
Condition: Anesthesia
Intervention: Drug: sugammadex
11 Completed Comparison of Sugammadex With Neostigmine Administered at 1-2 PTCs After Administration of Rocuronium or Vecuronium (19.4.302)(COMPLETED)
Condition: Anesthesia, General
Interventions: Drug: sugammadex;   Drug: neostigmine
12 Completed A Bridging Trial Comparing Org 25969 at 1-2 PTC in Japanese and Caucasian Subjects. Part B: Caucasian Subjects (19.4.209B)(COMPLETED)
Condition: Anesthesia, General
Interventions: Drug: Sugammadex;   Drug: Placebo
13 Completed A Bridging Trial Comparing Org 25969 at 1-2 PTC in Japanese and Caucasian Subjects. Part A: Japanese Subjects (19.4.209A)(COMPLETED)
Condition: Anesthesia, General
Interventions: Drug: Sugammadex;   Drug: Placebo
14 Completed Comparison Sugammadex Administered at 1-2 PTCs or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adult Subjects Undergoing Elective Open Abdominal Procedure (19.4.334)(COMPLETED)
Condition: Anesthesia
Interventions: Drug: sugammadex;   Drug: Neostigmine
15 Recruiting Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-Associated Cardiotoxicity
Condition: Breast Cancer
Interventions: Drug: placebo;   Drug: AT1 blocker candesartan
16 Recruiting Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody
Condition: Hypertension
Intervention: Drug: candesartan cilexetil
17 Recruiting Whole Body Magnetic Resonance Angiography in Ischemic Patients at 1.5 and 3T
Conditions: Atherosclerosis;   Intermittent Claudication;   MRI
Intervention:
18 Active, not recruiting Evaluation of the Avaulta Procedure for the Correction of Pelvic Organ Prolapse - Results at 1 Year
Condition: Pelvic Organ Prolapse
Intervention:
19 Not yet recruiting Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)
Conditions: Anesthesia, General;   Neuromuscular Relaxation
Intervention: Drug: Sugammadex
20 Recruiting Magnetic Resonance Imaging at Different Levels of Magnetic Intensity
Conditions: Cardiovascular Disease;   Healthy
Intervention:

Previous Page Studies Shown (1-20) Next (21-34)
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services